Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase...
Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Monlunabant?
Monlunabant is a small molecule commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata,...